Latest news with #drugmaker
Reuters
a day ago
- Business
- Reuters
CapVest eyes majority stake in German drugmaker Stada, Bloomberg News reports
July 22 (Reuters) - London-based buyout firm CapVest Partners is in talks to acquire a majority stake in German drugmaker Stada Arzneimittel, Bloomberg News reported on Tuesday. The deal would value Stada Arzneimittel at about 10 billion euros ($11.75 billion) including debt, the report said, citing unnamed sources. CapVest is in discussions with Stada's private equity owners, Bain Capital and Cinven, regarding the transaction. Stada has also been exploring a potential listing, the report said. CapVest declined comment, while Stada did not immediately respond to a Reuters' request for comment. Stada, known for its cold medicine Grippostad, sunscreen Ladival and the cough syrup Silomat in March, postponed a planned IPO in Frankfurt due to market volatility. Bankers advising Bain Capital and Cinven recommended against proceeding with the listing at that time, Reuters reported. ($1 = 0.8511 euros)
Bloomberg
a day ago
- Business
- Bloomberg
CapVest Is in Talks for Drugmaker Stada in €10 Billion Deal
By , Dinesh Nair, Eyk Henning, and Swetha Gopinath Save CapVest Partners is in talks to acquire a majority stake in Stada Arzneimittel AG in a deal that could value the German drugmaker at about €10 billion ($11.7 billion) including debt, people familiar with the matter said. The London-based buyout firm is in discussions with Stada's private equity owners, Bain Capital and Cinven, about a deal for the drugmaker, which has also been concurrently exploring a potential listing, the people said, asking not to be identified as the matter is private. The buyout shop has backing from large institutional firms in its bid for Stada, the people said.
Yahoo
2 days ago
- Business
- Yahoo
Biogen to invest $2 billion more in North Carolina
(Reuters) -Drugmaker Biogen (BIIB) said on Monday it will invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research Triangle Park. The company has invested about $10 billion in its North Carolina manufacturing to date. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Reuters
2 days ago
- Business
- Reuters
Drugmaker Biogen to invest $2 billion more in North Carolina
July 21 (Reuters) - Biogen (BIIB.O), opens new tab will invest an additional $2 billion in its existing manufacturing in North Carolina, the drugmaker said on Monday, as it seeks to expand its presence in the U.S. amid President Donald Trump's tariff threats. The company said the investment will go to its manufacturing plants in North Carolina's Research Triangle Park (RTP), which produce its major therapies for multiple sclerosis and Alzheimer's. Biogen has invested about $10 billion in its North Carolina manufacturing to date. The drugmaker said it plans to continue investing in multiple modalities and factories across its two campuses in RTP.
Yahoo
2 days ago
- Business
- Yahoo
Biogen to invest $2 billion more in North Carolina
(Reuters) -Drugmaker Biogen said on Monday it will invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research Triangle Park. The company has invested about $10 billion in its North Carolina manufacturing to date. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
